Star Metro - Datametrex Announces Participation in AlphaNorth Capital Event

NYSE - LSE

SCS	0.12%	16.14	$
RBGPF	0.12%	82.5	$
NGG	1.33%	88.06	$
RELX	-2.42%	29.38	$
RYCEF	1.54%	16.88	$
RIO	2.45%	93.41	$
CMSD	0.25%	23.95	$
BTI	1.34%	62.8	$
AZN	3.04%	193.03	$
CMSC	-0.17%	23.51	$
BCC	2.05%	91.03	$
BCE	-1.95%	25.08	$
JRI	0.69%	12.97	$
VOD	3.24%	15.11	$
BP	2.15%	39.01	$
GSK	1.76%	60.23	$

Datametrex Announces Participation in AlphaNorth Capital Event

TECHNOLOGY 15.01.2026

Datametrex Announces Participation in AlphaNorth Capital Event

TORONTO, ON / ACCESS Newswire / January 15, 2026 / Datametrex AI Limited (the "Company" or "Datametrex'') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce its participation in the upcoming AlphaNorth Capital Event, hosted by CEM, taking place January 16-18, 2026. The event introduces growth-stage companies across the Resource, Technology, Biotech, and Special Situations sectors to active capital markets participants through a full day of scheduled one-on-one meetings.

Text size:

Event information is available at https://cem.ca/conference/alphanorth-capital-event-2026.

Paul Haber, CEO of Datametrex, commented, "The AlphaNorth Capital Event provides an excellent platform to connect with professional investors and capital markets participants. We look forward to sharing Datametrex's progress, strategy, and growth initiatives with both existing shareholders and new prospective investors".

About Datametrex

Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, and Healthcare. The Company specializes in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology.

For more on Datametrex, please visit our Company website (www.datametrex.com).

For Additional Information

Paul Haber, C.P.A., C.A., C.Dir
CEO & Chairman
[email protected]
(416) 318-6501

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

Forward-Looking Statements

This news release contains "forward-looking statements," which involve risks, uncertainties, and factors that could cause actual results to differ materially from those anticipated. These statements are not historical facts and are generally identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," and similar expressions. Such statements include expectations related to healthcare business and other Company plans.

While Datametrex believes the forward-looking information is reasonable as of the date of this release, these statements involve assumptions, risks, and uncertainties that could cause actual outcomes to differ. Key factors include general economic conditions, legislative and regulatory developments, access to capital, industry competition, and the Company's ability to execute its strategies. The Company does not undertake to update these statements, except as required by law. Readers are advised not to place undue reliance on forward-looking information.

Factors that could cause actual results to differ materially are detailed under "Risk Factors" in Datametrex's management's discussion and analysis and available on the Company's profile at www.sedarplus.ca.

This release does not constitute an offer to sell or a solicitation to buy, nor shall it constitute an offer, solicitation, or sale in any jurisdiction where such would be unlawful prior to registration or qualification under applicable securities laws. We seek Safe Harbor.

###

SOURCE: Datametrex AI Ltd.

View the original press release on ACCESS Newswire

S.Lapointe--SMC

Featured

Amazon shares plunge as AI costs climb

Amazon shares dove more than 11 percent on Thursday as the computing and retail titan reported strong sales but significantly boosted spending estimates.

Greece aims to cut queues at ancient sites with new portal

Greece's culture ministry on Thursday unveiled a new portal to handle bookings to visit more than 100 archaeological sites and museums including the world-renowned Acropolis.

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce that it has commenced Project Phase 2 peptide design activities with Neuland Laboratories Limited ("Neuland") under the parties' existing services agreement (please see news release dated January 8, 2026).

CyberGuard Advantage Strengthens Executive Leadership Team with Key Appointments to Scale Global Operations

Dylan Anderson (CRO), Neetu Jindal (CHRO), and Jeni Bahr (CFO) join the cybersecurity and compliance leader to drive operational excellence and long-term growth.